X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

HIV And COVID-19 Vaccines Could Benefit From Nasal Release

Content Team by Content Team
23rd August 2022
in News, Research & Development
Glenmark and SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

A team led by an assistant professor from the University of Minnesota in the US has created a new method to successfully administer vaccines through the mucosal tissues in the nose, which could result in improved defence against pathogens like the COVID-19-causing SARS-CoV-2 virus and the human immunodeficiency virus (HIV).

The method was tested on mice and non-human primates, and the findings revealed that the vaccine produced potent immune function, opening the door for additional research and the creation of nasal vaccines.

The study appeared in the American Association for the Advancement of Science’s interdisciplinary medical journal Science Translational Medicine (AAAS).

Nasal vaccinations, which are given by a nebulizer or spray, have historically been challenging to successfully manufacture. Before the vaccine’s ingredients, such as protein antigens, can reach deeper tissues and trigger the body’s immune cells, mucus in the nose usually clears them out or breaks them down.

However, nasal vaccinations have the potential to increase immunity much further than the current immunizations given via needle injection. This is because nasal vaccinations have the ability to elicit immune responses in the precise sites of infection- the nose, mouth, and lungs for many diseases that are spread through the upper respiratory system, such as COVID-19. There are some nasal vaccines; however, the majority employ live virus pathogens, which cannot be administered to immunocompromised individuals.

The first author of the study and an assistant professor in the department of biomedical engineering at the University of Minnesota Twin Cities, Brittany Hartwell, said conventional vaccines that are administered intravenously are typically not designed to establish immunity in these mucosal tissues. They are primarily focused on building up immunity in the blood, acting as a type of back-up defence. However, the objective behind developing immunity in mucosal regions, such as the nose, is that it creates a stronger first line of defence that can better prevent the spread of these infections.

In addition to establishing a powerful mucosal immune reaction, Hartwell claimed that this novel vaccination also stimulated powerful antibody responses in the blood. So, she explained, it’s kind of like researchers are setting up a frontline and reserve defence at the same time.

In order to help vaccination antigens get past the mucosal barriers in the nose, Hartwell and her team engineered them to connect to a protein called albumin, which is present in the human body naturally and has the capacity to get beyond these barriers. The immunological tissues underneath the nose would be the antigens’ final destination, where they might start generating an immune response by effectively hitching a ride on albumin.

Additionally, the vaccine developed by the researchers was successful in promoting immunity not only in the nose but also in the upper respiratory system, the lungs, and the genitourinary tract. The latter is particularly important for immunising against viruses like HIV that are spread through those places.

For the domain of mucosal vaccination, this is highly important, according to Hartwell. It demonstrates a novel finding- they have created a vaccine that can get beyond delivery obstacles that have previously hampered the creation of other mucosal vaccinations. People are all currently experiencing the COVID pandemic, which is still having an impact on their daily lives, so it is especially pertinent at this time. Additionally, the virus has the possibility to develop new variations with the ability to be hazardous as long as there is dissemination and transmission. This research indicates the creation of a somewhat different type of vaccination that, by prohibiting transmission and offering even more coverage than what we now have, could be developed.

In her lab at the University of Minnesota Twin Cities, Hartwell is working to further develop and analyse this novel vaccine technology with the goal of eventually applying it to other ailments and diseases.

Previous Post

Enhertu of Daiichi Sankyo, AZ Gains HER2-Mutant Lung Cancer

Next Post

Study Identifies And Closes Gaps In Some High-Risk Cancers

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Study Identifies And Closes Gaps In Some High-Risk Cancers

Study Identifies And Closes Gaps In Some High-Risk Cancers

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In